PA-ADVA-OPTICAL
21.6.2022 09:02:07 CEST | Business Wire | Press release
ADVA (FSE: ADV) and II‐VI Incorporated (Nasdaq: IIVI), today launched the industry’s first 100ZR pluggable coherent transceiver. Jointly defined and purpose-built for the optical network edge, the Coherent 100ZR is rated for both commercial- and industrial-temperature (C-temp and I-temp) operating ranges. The new 100ZR digital coherent optics (DCO) transceiver features the Steelerton™ coherent digital signal processor (DSP). Co-funded by both companies, this all-new DSP is completely unique to the marketplace.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220620005288/en/
The rapid growth of data traffic in 5G wireless and broadband access networks is driving demand for next-generation transmission technology that enables service providers to expand the capacity of their bandwidth aggregation infrastructure at the edge of the network. The new Coherent 100ZR transceiver now empowers service providers to deploy 100Gbit/s coherent transceiver technology in the access network easily and affordably. These benefits are achieved thanks to the transceiver‘s unique features, including a coherent DSP optimized for 100ZR, cost-efficient silicon photonics technology, a standard QSFP28 interface, and Flextune™ technology.
“With this new application-specific transceiver technology, service providers can now benefit from the simplicity and robustness of coherent technology in the access network and seamlessly upgrade millions of 10Gbit/s Ethernet links to 100Gbit/s,” said Henning Hinderthür, VP of product line management at ADVA. “While this product design is perfectly tailored to this application, it will also achieve economies of scale by leveraging II-VI’s track record of manufacturing transceivers in high volume.”
“We’ve had great feedback from both carriers and OEMs on this product, and are pleased to partner with ADVA on this key milestone for the industry,” said Matthias Berger, VP of coherent technology at II-VI Incorporated. “The transceiver includes the Steelerton™ DSP, a first-of-its-kind and game-changing coherent processor, due to its small size and low power consumption, which are both key to achieving the standard QSFP28 power dissipation requirement of less than 5 watts. What makes this transceiver even more compelling for carriers is the embedded auto-tunable Flextune™ technology, which lowers operational expenses by simplifying network deployments. It’s the ideal combination of cost-effective coherent technology with plug-and-play ease of use.”
The new Coherent 100ZR transceiver plugs directly into existing head-ends, switches, and routers, enabling existing network elements to transmit 100Gbit/s signals over links stretching up to several hundred kilometers. The 100ZR transceivers are offered in both C-temp and I-temp variations to meet a broad range of deployment options, including central offices and local exchanges, as well as in more challenging ambient environments, such as street cabinets.
Further details on ADVA’s Coherent 100ZR are available in these slides: https://adva.li/coherent-100zr-slides .
A supporting product video is also available here: https://youtu.be/XYWckbTxB3M .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About II-VI Incorporated
II-VI Incorporated, a global leader in engineered materials and optoelectronic components, is a vertically integrated manufacturing company that develops innovative products for diversified applications in communications, industrial, aerospace & defense, semiconductor capital equipment, life sciences, consumer electronics, and automotive markets. Headquartered in Saxonburg, Pennsylvania, the Company has research and development, manufacturing, sales, service, and distribution facilities worldwide. The Company produces a wide variety of application-specific photonic and electronic materials and components, and deploys them in various forms, including integrated with advanced software to support our customers. For more information, please visit us at www.ii-vi.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005288/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 12:30:00 CEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 12:00:00 CEST | Press release
Aker BP joins as the first customer to scale agent-to-agent operations through a new generation of industrial agentic workflow applications Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 12:00:00 CEST | Press release
Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatmentThree oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipeline BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data undersco
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
